Influenza virus still poses a major threat to human health. Despite widespread vaccination programmes and the development of drugs targeting essential viral proteins, the extremely high mutation rate of influenza virus still leads to the emergence of new pathogenic virus strains. Therefore, it has been suggested that cellular cofactors that are essential for influenza virus infection might be better targets for antiviral therapy. It has previously been reported that influenza virus efficiently infects Epstein–Barr virus-immortalized B cells, whereas Burkitt's lymphoma cells are virtually resistant to infection. Using this cellular system, it has been shown here that an active NF-κB signalling pathway is a general prerequisite for influenza virus infection of human cells. Cells with low NF-κB activity were resistant to influenza virus infection, but became susceptible upon activation of NF-κB. In addition, blocking of NF-κB activation severely impaired influenza virus infection of otherwise highly susceptible cells, including the human lung carcinoma cell lines A549 and U1752 and primary human cells. On the other hand, infection with vaccinia virus was not dependent on an active NF-κB signalling pathway, demonstrating the specificity of this pathway for influenza virus infection. These results might be of major importance for both the development of new antiviral therapies and the understanding of influenza virus biology.
AlizadehA. A.,
EisenM. B.,
DavisR. E.28 other authors2000; Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511[CrossRef]
AzzehM.,
FlickR.,
HobomG.2001; Functional analysis of the influenza A virus cRNA promoter and construction of an ambisense transcription system. Virology 289:400–410[CrossRef]
BridgesC. B.,
HarperS. A.,
FukudaK.,
UyekiT. M.,
CoxN. J.,
SingletonJ. A.2003; Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep521–34 quiz CE1–4
DudziakD.,
KieserA.,
DirmeierU.7 other authors2003; Latent membrane protein 1 of Epstein–Barr virus induces CD83 by the NF- κ B signaling pathway. J Virol 77:8290–8298[CrossRef]
FloryE.,
KunzM.,
SchellerC.,
JassoyC.,
StauberR.,
RappU. R.,
LudwigS.2000; Influenza virus-induced NF- κ B-dependent gene expression is mediated by overexpression of viral proteins and involves oxidative radicals and activation of I κ B kinase. J Biol Chem 275:8307–8314[CrossRef]
Garcia-SastreA.2001; Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 279:375–384[CrossRef]
GeissG. K.,
SalvatoreM.,
TumpeyT. M.8 other authors2002; Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A 99:10736–10741[CrossRef]
GubarevaL. V.,
WebsterR. G.,
HaydenF. G.2002; Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 53:47–61[CrossRef]
HuenD. S.,
HendersonS. A.,
Croom-CarterD.,
RoweM.1995; The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF- κ B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549–560
InoueK.,
SuzukiS.,
KuboH.,
UedaS.,
KondoT.2003; Effects of rewarming on nuclear factor- κ B and interleukin 8 expression in cold-preserved alveolar epithelial cells. Transplantation 76:409–415[CrossRef]
KaufmanJ.,
GrafB. A.,
LeungE. C.,
PollockS. J.,
KoumasL.,
ReddyS. Y.,
BliedenT. M.,
SmithT. J.,
PhippsR. P.2001; Fibroblasts as sentinel cells: role of the CD40–CD40 ligand system in fibroblast activation and lung inflammation and fibrosis. Chest 120:53S–55S[CrossRef]
KempkesB.,
Zimber-StroblU.,
EissnerG.,
PawlitaM.,
FalkM.,
HammerschmidtW.,
BornkammG. W.1996; Epstein–Barr virus nuclear antigen 2 (EBNA2)–oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein–Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. J Gen Virol 77:227–237[CrossRef]
MitchellT.,
SugdenB.1995; Stimulation of NF- κ B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein–Barr virus. J Virol 69:2968–2976
PajicA.,
SpitkovskyD.,
ChristophB.9 other authors2000; Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer 87:787–793[CrossRef]
PierceJ. W.,
SchoenleberR.,
JesmokG.,
BestJ.,
MooreS. A.,
CollinsT.,
GerritsenM. E.1997; Novel inhibitors of cytokine-induced I κ B α phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096–21103[CrossRef]
PleschkaS.,
WolffT.,
EhrhardtC.,
HobomG.,
PlanzO.,
RappU. R.,
LudwigS.2001; Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 3:301–305[CrossRef]
PolackA.,
HortnagelK.,
PajicA.7 other authors1996; c-Myc activation renders proliferation of Epstein–Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci U S A 93:10411–10416[CrossRef]
RootC. N.,
WillsE. G.,
McNairL. L.,
WhittakerG. R.2000; Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor. J Gen Virol 81:2697–2705
ScholtissekC.,
MullerK.1991; Failure to obtain drug-resistant variants of influenza virus after treatment with inhibiting doses of 3-deazaadenosine and H7. Arch Virol 119:111–118[CrossRef]
ScholtissekC.,
StechJ.,
KraussS.,
WebsterR. G.2002; Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses. J Virol 76:1781–1786[CrossRef]
ShortridgeK. F.,
GaoP.,
GuanY.,
ItoT.,
KawaokaY.,
MarkwellD.,
TakadaA.,
WebsterR. G.2000; Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. Vet Microbiol 74:141–147[CrossRef]
SieczkarskiS. B.,
BrownH. A.,
WhittakerG. R.2003; Role of protein kinase C β II in influenza virus entry via late endosomes. J Virol 77:460–469[CrossRef]
TashiroM.,
CiborowskiP.,
KlenkH. D.,
PulvererG.,
RottR.1987; Role of Staphylococcus protease in the development of influenza pneumonia. Nature 325:536–537[CrossRef]
ThompsonW. W.,
ShayD. K.,
WeintraubE.,
BrammerL.,
CoxN.,
AndersonL. J.,
FukudaK.2003; Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (J Am Med Assoc) 289:179–186[CrossRef]
WagnerR.,
WolffT.,
HerwigA.,
PleschkaS.,
KlenkH. D.2000; Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol 74:6316–6323[CrossRef]
Zimber-StroblU.,
KempkesB.,
MarschallG.,
ZeidlerR.,
Van KootenC.,
BanchereauJ.,
BornkammG. W.,
HammerschmidtW.1996; Epstein–Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J 15:7070–7078